IMAX•November 18, 2026 at 1:30 PM UTCMedia & Entertainment

IMAX Elevates Commercial Chief to New COO Role; No Change to WAIT Thesis

Read source article

What happened

IMAX promoted Giovanni Dolci to the newly created role of COO, expanding his responsibilities to include Global Theatres and Technology while he continues as Chief Commercial Officer. The move formalizes operational leadership under CEO Rich Gelfond but does not alter the core business model or near-term catalysts, which remain dependent on premium-format share and backlog recovery. The latest DeepValue analysis rates IMAX a WAIT with conviction 3.5, as the stock at ~$43 already prices in a strong 2H 2026 slate and stable global share near 3.7%, still below the 2025 record of 3.8%. Management quality was assessed as adequate, with transparent disclosures on China backlog impairments, and this promotion is consistent with that steady stewardship rather than a strategic pivot. Investors should therefore treat this news as a non-event for fundamentals, with attention instead on the next 10-Q for evidence that backlog attrition has stopped and ex-China signings are replenishing growth.

Implication

For investors, the promotion is a neutral to slightly positive governance signal, showing depth in management but not solving the company's core issues: a shrinking backlog (421 vs 501 a year ago) and trailing global share below the 2025 record. The stock's valuation at 57.8x P/E and 18.8x EV/EBITDA leaves no margin of safety, so any entry should wait for a pullback toward $37 or confirmation in the next filing that share has reclaimed 3.8% and China cancellations have ceased. Dolci's expanded role overseeing technology and global theatres could improve execution on installation conversions and non-China growth, but the effects will take quarters to show in financials. The master report sets a trim level above $48, implying that current levels near $43 offer limited upside unless the bullish scenario materializes, which requires share above 3.9% and backlog above 435. Until those thresholds are met, the WAIT rating stands, and the recommended action is to monitor 90-day checkpoints such as the next 10-Q for signings and box-office trends.

Thesis delta

The COO appointment does not alter the investment thesis, which remains a WAIT based on a full valuation and unresolved China backlog risks. The promotion may marginally improve operational execution over time, but it does not change the pivotal metrics: trailing global share (3.7%) and backlog (421) need to improve before any upgrade. Accordingly, the thesis delta is zero; the stock still requires either a lower entry price or hard evidence of reaccelerating network growth.

Confidence

High